{
    "clinical_study": {
        "@rank": "23448", 
        "acronym": "PLATO", 
        "arm_group": [
            {
                "arm_group_label": "Enzalutamide & Abiraterone", 
                "arm_group_type": "Experimental", 
                "description": "Enzalutamide (160 mg) administered as four 40-mg capsules by mouth once daily in combination with abiraterone (1000 mg) administered as four 250-mg tablets by mouth once daily and prednisone (10 mg) administered as one 5-mg tablet by mouth twice daily"
            }, 
            {
                "arm_group_label": "Enzalutamide placebo & Abiraterone", 
                "arm_group_type": "Active Comparator", 
                "description": "Enzalutamide placebo (placebo) capsules (identical in appearance to enzalutamide) administered as 4 capsules by mouth once daily in combination with abiraterone (1000 mg) administered as four 250-mg tablets by mouth once daily and prednisone (10 mg) administered as one 5-mg tablet by mouth twice daily."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine if continued treatment with Enzalutamide is\n      effective in patients with metastatic prostate cancer."
        }, 
        "brief_title": "Safety Study of Continued Enzalutamide Treatment In Prostate Cancer Patients", 
        "completion_date": {
            "#text": "September 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Prostate Cancer", 
        "condition_browse": {
            "mesh_term": "Prostatic Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Men with metastatic castration-resistant prostate cancer\n\n          -  Progressive disease on androgen deprivation therapy\n\n          -  Patients must agree to continue androgen deprivation therapy with a GnRH\n             agonist/antagonist throughout the study or have had a prior bilateral orchiectomy\n\n          -  ECOG performance score \u2264 1\n\n          -  Estimated life expectancy of \u2265 12 months\n\n        Exclusion Criteria:\n\n          -  Prior cytotoxic chemotherapy, aminoglutethimide, ketoconazole, abiraterone, or\n             enzalutamide for the treatment of prostate cancer\n\n          -  Prior participation in a clinical trial of an investigational agent that inhibits the\n             androgen receptor or androgen synthesis (unless the treatment was placebo)\n\n          -  History of brain metastasis, active leptomeningeal disease or seizure\n\n          -  Severe cardiovascular or hepatic disease\n\n          -  Pituitary or adrenal dysfunction"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "500", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 18, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01995513", 
            "org_study_id": "MDV3100-10"
        }, 
        "intervention": [
            {
                "arm_group_label": "Enzalutamide & Abiraterone", 
                "description": "160 mg by mouth once daily", 
                "intervention_name": "Enzalutamide", 
                "intervention_type": "Drug", 
                "other_name": [
                    "MDV3100", 
                    "Xtandi"
                ]
            }, 
            {
                "arm_group_label": [
                    "Enzalutamide & Abiraterone", 
                    "Enzalutamide placebo & Abiraterone"
                ], 
                "description": "1000 mg by mouth once daily", 
                "intervention_name": "Abiraterone", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Abiraterone acetate", 
                    "Zytiga"
                ]
            }, 
            {
                "arm_group_label": "Enzalutamide placebo & Abiraterone", 
                "description": "Sugar pill manufactured to mimic Enzalutamide 40 mg capsule", 
                "intervention_name": "Placebo for Enzalutamide", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Enzalutamide & Abiraterone", 
                    "Enzalutamide placebo & Abiraterone"
                ], 
                "description": "5 mg by mouth twice daily", 
                "intervention_name": "Prednisone", 
                "intervention_type": "Drug", 
                "other_name": "prednisolone"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Prednisolone", 
                "Prednisone"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "March 10, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Virginia Beach", 
                        "country": "United States", 
                        "state": "Virginia", 
                        "zip": "23462"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Concord", 
                        "country": "Australia", 
                        "state": "New South Wales", 
                        "zip": "2139"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "North Ryde", 
                        "country": "Australia", 
                        "state": "New South Wales", 
                        "zip": "2109"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Port Macquarie", 
                        "country": "Australia", 
                        "state": "New South Wales", 
                        "zip": "2444"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sydney", 
                        "country": "Australia", 
                        "state": "New South Wales", 
                        "zip": "2076"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tweed Heads", 
                        "country": "Australia", 
                        "state": "New South Wales", 
                        "zip": "2485"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Wahroonga", 
                        "country": "Australia", 
                        "state": "New South Wales", 
                        "zip": "2076"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Milton", 
                        "country": "Australia", 
                        "state": "Queensland", 
                        "zip": "4064"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kurralta Park", 
                        "country": "Australia", 
                        "state": "South Australia", 
                        "zip": "5037"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bentleigh East", 
                        "country": "Australia", 
                        "state": "Victoria", 
                        "zip": "3165"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Wodonga", 
                        "country": "Australia", 
                        "state": "Victoria", 
                        "zip": "3690"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Oulu", 
                        "country": "Finland", 
                        "zip": "90220"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tampere", 
                        "country": "Finland", 
                        "zip": "33520"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sutton", 
                        "country": "United Kingdom", 
                        "state": "Surrey", 
                        "zip": "SM2 5PT"
                    }
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Australia", 
                "Finland", 
                "United Kingdom"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 4, Randomized, Double-Blind, Placebo-Controlled Study of Continued Enzalutamide Treatment Beyond Progression in Patients With Chemotherapy-Na\u00efve Metastatic Castration-Resistant Prostate Cancer", 
        "overall_contact": {
            "email": "Corina.Andresen@medivation.com", 
            "last_name": "Corina Andresen, MD", 
            "phone": "415-432-6670"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Progression Free Survival (PFS)", 
            "safety_issue": "No", 
            "time_frame": "Every two months following randomization for up to 50 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01995513"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Time to PSA Progression", 
                "safety_issue": "No", 
                "time_frame": "Every two months following randomization for up to 50 months"
            }, 
            {
                "measure": "PSA Response", 
                "safety_issue": "No", 
                "time_frame": "Every two months following randomization for up to 50 months"
            }
        ], 
        "source": "Medivation, Inc.", 
        "sponsors": {
            "collaborator": {
                "agency": "Astellas Pharma Inc", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Medivation, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}